Diverse Portfolio
SMPA is committed to accelerating scientific and therapeutic breakthroughs in key areas of unique and unmet medical need including oncology, urology, women's health, rare disease, CNS, and cell and gene therapies.
About Us
We are united in our mission to advance scientific understanding and deliver meaningful and differentiated therapies that improve the lives of patients in areas of unique and unmet need across multiple therapeutic areas.
We are curious, bold, and share a passion for thinking differently.
Our Origins
Building on deep heritage, SMPA brings the 100-year history of Sumitomo Pharma Group's extensive global impact supporting the health and well-being of communities in which we live and work.
Formed through the consolidation of Sumitomo Pharma's seven U.S. affiliate companies, SMPA is a Sumitomo Pharma company and is a member of the Sumitomo Group, which has a rich, 400-year history.
Learn More About Sumitomo Pharma Co., Ltd. ›Learn more about the innovative work our teams are collaborating on in regenerative medicine and rare disease to meet unmet patient needs.
OUR TEAM
We are industry-leading experts in drug development, business, tissue engineering, and science. Together, we operate with rigor, flexibility, and compassion to deliver life-changing treatments that address unique and unmet patient needs.
Leadership
Tsutomu Nakagawa, Ph.D.
President & Chief Executive Officer
Betzy Estrada
Chief Human Resources Officer
Ron Gimbel
Chief Financial Officer
Andrew Hetherington, MBA
Chief Technology & Quality Officer
Kimihiro Mizuno
Chief Corporate Officer
Yumi Sato
Chief Development Officer
Jatin Shah, M.D.
Chief Medical Officer - Oncology
Tara Soni
Chief Legal Officer
Kenton Stewart
Chief Commercial Officer
Board of Directors
Tsutomu Nakagawa, Ph.D.
President & Chief Executive Officer, Sumitomo Pharma America
Toru Kimura
Representative Director, President and CEO, Sumitomo Pharma
Motoyuki Sakai
Representative Director, Executive Vice President, Sumitomo Pharma
Yumi Sato
Member, Board of Directors, Chief Development Officer, Sumitomo Pharma America
Ron Gimbel
Member, Board of Directors, Chief Financial Officer, Sumitomo Pharma America
TECHNOLOGY
Unlocking innovative science and solutions through cutting-edge technology.
Advanced in-house technology platforms and data analytics capabilities are accelerating insights in science, research, and discovery. Our platforms work to de-risk and optimize clinical and commercial programs to accelerate innovative solutions and patient-first outcomes.
Information Security & Certifications
The Information Security Program overseeing SMPA's manufacturing operations is ISO/IEC 27001:2022 certified.
Our Reach
Global reach with an expansive U.S. footprint
SMPA is part of a global ecosystem of companies working on innovative research and development activities to transform healthcare and improve the lives of people worldwide. This global ecosystem has a geographic footprint spanning Japan, the U.S., and Europe as well as talent, knowledge, and resources across a wide spectrum of technologies and therapeutic areas.
Contact Us